Literature DB >> 27590036

Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC-MS/MS in Postmortem Casework.

Amanda L A Mohr1, Melissa Friscia1, Donna Papsun2, Sherri L Kacinko2, David Buzby2, Barry K Logan3,2.   

Abstract

Following series of synthetic cannabinoid and synthetic cathinone derivatives, the illicit drug market has begun to see increased incidence of synthetic opioids including fentanyl and its derivatives, and other chemically unrelated opioid agonists including AH-7921 and MT-45. Among the most frequently encountered compounds in postmortem casework have been furanyl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide, Fu-F) and U-47700 (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide). Both drugs have been reported to be present in the heroin supply and to be gaining popularity among recreational opioid users, but were initially developed by pharmaceutical companies in the 1970s as candidates for development as potential analgesic therapeutic agents. A method was developed and validated for the analysis of U-47700, U-50488 and furanyl fentanyl in blood specimens. A total of 20 postmortem cases, initially believed to be heroin or other opioid-related drug overdoses, were submitted for quantitative analysis. The analytical range for U-47770 and U-50488 was 1-500 and 1-100 ng/mL for furanyl fentanyl. The limit of detection was 0.5 ng/mL for all compounds. Within the scope of the method, U-47700 was the only confirmed drug in 11 of the cases, 5 cases were confirmed for both U-47700 and furanyl fentanyl, and 3 cases were confirmed only for furanyl fentanyl. The mean and median blood concentrations for U-47700 were 253 ng/mL (±150) and 247 ng/mL, respectively, range 17-490 ng/mL. The mean and median blood concentrations for furanyl fentanyl were 26 ng/mL (±28) and 12.9 ng/mL, respectively, range 2.5-76 ng/mL. Given the widespread geographical distribution and increase in prevalence in postmortem casework, toxicology testing should be expanded to include testing for "designer opioids" in cases with histories consistent with opioid overdose but with no traditional opioids present or insufficient quantities to account for death.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27590036     DOI: 10.1093/jat/bkw086

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  35 in total

1.  Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace.

Authors:  Michael H Baumann; Susruta Majumdar; Valerie Le Rouzic; Amanda Hunkele; Rajendra Uprety; Xi Ping Huang; Jin Xu; Bryan L Roth; Ying-Xian Pan; Gavril W Pasternak
Journal:  Neuropharmacology       Date:  2017-08-12       Impact factor: 5.250

2.  Postmortem concentration distribution in fatal cases involving the synthetic opioid U-47700.

Authors:  Marek Dziadosz; Michael Klintschar; Jörg Teske
Journal:  Int J Legal Med       Date:  2017-04-11       Impact factor: 2.686

3.  Another fatal case related to the recreational abuse of U-47700.

Authors:  Nadine Strehmel; Denise Dümpelmann; Elke Vejmelka; Veronika Strehmel; Sonja Roscher; Stefan Scholtis; Michael Tsokos
Journal:  Forensic Sci Med Pathol       Date:  2018-09-18       Impact factor: 2.007

4.  Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg?

Authors:  Michael H Baumann; Gavril W Pasternak
Journal:  Neuropsychopharmacology       Date:  2018-01       Impact factor: 7.853

5.  Fatalities associated with NPS stimulants in the Greater Cologne area.

Authors:  Sabrina Lehmann; Tobias Kieliba; Mario Thevis; Markus A Rothschild; Katja Mercer-Chalmers-Bender
Journal:  Int J Legal Med       Date:  2019-11-18       Impact factor: 2.686

6.  Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700.

Authors:  Camille Richeval; Jean-Michel Gaulier; Ludovic Romeuf; Delphine Allorge; Yvan Gaillard
Journal:  Int J Legal Med       Date:  2018-11-15       Impact factor: 2.686

7.  A Novel Oral Fluid Assay (LC-QTOF-MS) for the Detection of Fentanyl and Clandestine Opioids in Oral Fluid After Reported Heroin Overdose.

Authors:  Matthew K Griswold; Peter R Chai; Alex J Krotulski; Melissa Friscia; Brittany P Chapman; Neha Varma; Edward W Boyer; Barry K Logan; Kavita M Babu
Journal:  J Med Toxicol       Date:  2017-10-02

8.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

9.  Opioid-Associated Deaths in South Carolina, 2013-2016: A Retrospective Review.

Authors:  Daniel C Butler; Nicholas I Batalis
Journal:  Acad Forensic Pathol       Date:  2017-12-01

10.  Listed for sale: Analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket.

Authors:  Francois R Lamy; Raminta Daniulaityte; Monica J Barratt; Usha Lokala; Amit Sheth; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2020-06-12       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.